Aegis Capital reiterated coverage on Avinger with a new price target
$AVGR
Medical/Dental Instruments
Health Care
Aegis Capital reiterated coverage of Avinger with a rating of Buy and set a new price target of $2.00 from $2.50 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2021 | $2.50 → $2.00 | Buy | Aegis Capital |
| 6/29/2021 | $2.50 | Buy | B. Riley Securities |
REDWOOD CITY, CA / ACCESSWIRE / August 5, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the appointment of Thomas P. Davis, MD, FACC, as Chief Medical Officer for its peripheral business. As a highly experienced interventional cardiologist and key opinion leader (KOL) in the peripheral vascular space, Dr. Davis has operated at the forefront of medical device innovation and advancing patient care in a career spanning more than three decades. Dr. Davis has pioneered the use of several cutting-edge interventional technolo
SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek
REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020. At the Annual Meeting, proposals were presented to elect one director to serve until the 2023 annual meeting, to ratify the appointment of the Company's public accountant for the year ended December 31, 2020, to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock spl
SC 13G - Avinger Inc (0001506928) (Subject)
SC 13G/A - Avinger Inc (0001506928) (Subject)
SC 13G - Avinger Inc (0001506928) (Subject)
Aegis Capital reiterated coverage of Avinger with a rating of Buy and set a new price target of $2.00 from $2.50 previously
B. Riley Securities initiated coverage of Avinger with a rating of Buy and set a new price target of $2.50
3 - Avinger Inc (0001506928) (Issuer)
4 - Avinger Inc (0001506928) (Issuer)
4 - Avinger Inc (0001506928) (Issuer)
8-K - Avinger Inc (0001506928) (Filer)
10-Q - Avinger Inc (0001506928) (Filer)
DEFA14A - Avinger Inc (0001506928) (Filer)
Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development
REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co
REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease hosted a physician-focused webinar entitled, "New Approaches to Treating Peripheral Artery Disease (PAD) Below-the-Knee (BTK) and Promising New BTK Data." A recording of the webinar may be accessed at https://pages.avinger.com/webinar-new-approaches-to-treating-btk-pad.The webinar featured key opinion leaders in the field of vascular intervention from different specialties and geographies as follows:Dr. Michael Lichtenberg, an angiologist and the
Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development
REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co
REDWOOD CITY, CA / ACCESSWIRE / July 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2024 after the close of trading on Thursday, August 8, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1-848-280-6550 and use passcode Avinger. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.com.A
Shares of Streamline Health Solutions, Inc. (NASDAQ:STRM) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results. Streamline Health reported quarterly losses of 5 cents per share which missed the analyst consensus estimate of 4 cents per share. The company reported quarterly sales of $4.33 million which beat the analyst consensus estimate of $4.31 million, according to data from Benzinga Pro. Streamline Health Solutions shares dipped 23.3% to $0.4902 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers DDC Enterprise Limited (NYSE:DDC) surged 101% to $1.04. DDC Enterprise said it has acqu
Gainers Longeveron (NASDAQ:LGVN) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. vTv Therapeutics (NASDAQ:VTVT) stock increased by 43.09% to $26.0. The market value of their outstanding shares is at $63.2 million. Avidity Biosciences (NASDAQ:RNA) shares increased by 32.32% to $38.27. The company's market cap stands at $3.6 billion. Cyclerion Therapeutics (NASDAQ:CYCN) stock rose 30.39% to $2.96. The company's market cap stands at $7.3 million. Telesis Bio (NASDAQ:TBIO) stock moved upwards by 22.53% to $3.86. The company's market cap stands at $6.4 million. Autonomix Medical (NASDAQ:AMIX) stock rose 20.94%